SCHEMBL26075686

SCHEMBL26075686

Cc1ccc(NS(=O)(=O)c2cc(F)ccc2F)c(F)c1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 1/20 0.48
CYP2C19 P33261 2/20 0.48
MCL1 Q07820 2/20 0.47
CYP2C9 P11712 3/20 0.44
CCR2 P41597 1/20 0.42
ERN1 O75460 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
IDH1 O75874 1/20 0.42
ACLY P53396 1/20 0.41
CYP3A4 P08684 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BRD4 O60885 1/20 0.41
BRAF P15056 1/20 0.41
MEP1B Q16820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074500 0.90 GAA (0.44) PTGES2CYP2C19MCL1ALDH1A1LMNA
SCHEMBL26074499 0.85 TSHR (0.48) PTGES2CCR2ALDH1A1LMNATSHR
SCHEMBL26074505 0.80 MRGPRX1 (0.53) PTGES2MCL1MAPTIDH1ACLY
SCHEMBL3020003 0.79 PTGES2 (0.53) PTGES2CYP2C19CYP2C9CCR2ERN1
SCHEMBL26074502 0.78 SLC40A1 (0.43) PTGES2CYP2C19CCR2ERN1IDH1
SCHEMBL25450295 0.77 MCL1 (0.51) PTGES2CYP2C19MCL1CCR2ALDH1A1
SCHEMBL22531925 0.77 MCL1 (0.51) PTGES2CYP2C19MCL1CCR2ALDH1A1
SCHEMBL26075677 0.77 ALDH1A1 (0.51) PTGES2CYP2C19MCL1CCR2ALDH1A1
SCHEMBL26074503 0.76 SLC22A12 (0.60) CYP2C19CYP2C9ALDH1A1CYP3A4TSHR
SCHEMBL30161625 0.76 PTGES2 (0.50) PTGES2CYP2C19CYP2C9CCR2ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 PTGES2 1727/4885CYP2C19 1484/4885MCL1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.